This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Seratrodast
Accession Number
DB06739
Type
Small Molecule
Groups
Approved
Description

Seratrodast (INN) is a thromboxane receptor antagonist used primarily in the treatment of asthma.

Structure
Thumb
Synonyms
Not Available
External IDs
A-73001 / AA-2414 / ABBOTT 73001 / ABBOTT-73001 / ABT-001
International/Other Brands
Bronica
Categories
UNII
4U58JM421N
CAS number
112665-43-7
Weight
Average: 354.446
Monoisotopic: 354.183109317
Chemical Formula
C22H26O4
InChI Key
ZBVKEHDGYSLCCC-UHFFFAOYSA-N
InChI
InChI=1S/C22H26O4/c1-14-15(2)22(26)20(16(3)21(14)25)18(17-10-6-4-7-11-17)12-8-5-9-13-19(23)24/h4,6-7,10-11,18H,5,8-9,12-13H2,1-3H3,(H,23,24)
IUPAC Name
7-phenyl-7-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)heptanoic acid
SMILES
CC1=C(C)C(=O)C(C(CCCCCC(O)=O)C2=CC=CC=C2)=C(C)C1=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UThromboxane A2 receptor
antagonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when Seratrodast is combined with (4R)-limonene.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Seratrodast is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Seratrodast is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Seratrodast is combined with 5-androstenedione.Experimental, Illicit
AbciximabSeratrodast may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe serum concentration of Seratrodast can be increased when it is combined with Abiraterone.Approved
AcebutololSeratrodast may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Seratrodast is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Seratrodast is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolSeratrodast may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
Acetyl sulfisoxazoleThe metabolism of Seratrodast can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Seratrodast is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Seratrodast.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Seratrodast is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Seratrodast is combined with Alendronic acid.Approved
AliskirenSeratrodast may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Seratrodast is combined with Alminoprofen.Experimental
AlprenololSeratrodast may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Seratrodast.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Seratrodast is combined with Amcinonide.Approved
AmilorideSeratrodast may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Seratrodast is combined with Aminosalicylic Acid.Approved
AmiodaroneThe metabolism of Seratrodast can be decreased when combined with Amiodarone.Approved, Investigational
AncrodSeratrodast may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Seratrodast.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Seratrodast is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Seratrodast is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Seratrodast is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Seratrodast is combined with Antipyrine.Approved, Investigational
Antithrombin III humanSeratrodast may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Seratrodast is combined with Antrafenine.Approved
ApalutamideThe serum concentration of Seratrodast can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanSeratrodast may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Seratrodast is combined with Apocynin.Investigational
ApramycinSeratrodast may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Seratrodast.Approved, Investigational
AprepitantThe serum concentration of Seratrodast can be increased when it is combined with Aprepitant.Approved, Investigational
ArbekacinSeratrodast may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinSeratrodast may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanSeratrodast may increase the anticoagulant activities of Argatroban.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Seratrodast.Approved, Investigational
ArmodafinilThe metabolism of Seratrodast can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololSeratrodast may decrease the antihypertensive activities of Arotinolol.Investigational
ArtesunateThe serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Seratrodast resulting in a loss in efficacy.Approved, Investigational
AsenapineSeratrodast may decrease the antihypertensive activities of Asenapine.Approved
AsunaprevirThe serum concentration of Asunaprevir can be decreased when it is combined with Seratrodast.Approved, Investigational, Withdrawn
AtamestaneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Atamestane.Investigational
AtazanavirThe metabolism of Seratrodast can be decreased when combined with Atazanavir.Approved, Investigational
AtenololSeratrodast may decrease the antihypertensive activities of Atenolol.Approved
AtomoxetineThe metabolism of Seratrodast can be decreased when combined with Atomoxetine.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Seratrodast.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Seratrodast is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Seratrodast.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Seratrodast.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Seratrodast is combined with Balsalazide.Approved, Investigational
BecaplerminSeratrodast may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BefunololSeratrodast may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinSeratrodast may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Seratrodast is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Seratrodast is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Seratrodast.Approved
BenorilateThe risk or severity of adverse effects can be increased when Seratrodast is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Seratrodast.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Seratrodast.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Seratrodast is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Seratrodast.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Betamethasone.Approved, Vet Approved
BetaxololSeratrodast may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Seratrodast.Approved, Investigational
BevantololSeratrodast may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Seratrodast is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Seratrodast.Approved, Investigational
BisoprololSeratrodast may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinSeratrodast may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BoceprevirThe metabolism of Seratrodast can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololSeratrodast may decrease the antihypertensive activities of Bopindolol.Approved
BortezomibThe metabolism of Seratrodast can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Seratrodast can be decreased when it is combined with Bosentan.Approved, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Seratrodast is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Seratrodast is combined with Bucillamine.Investigational
BucindololSeratrodast may decrease the antihypertensive activities of Bucindolol.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Seratrodast is combined with Bufexamac.Approved, Experimental
BufuralolSeratrodast may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Bumadizone.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Seratrodast.Approved
BupranololSeratrodast may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Seratrodast.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Seratrodast.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Seratrodast is combined with Candoxatril.Experimental
CapecitabineThe metabolism of Seratrodast can be decreased when combined with Capecitabine.Approved, Investigational
CapsaicinThe risk or severity of adverse effects can be increased when Seratrodast is combined with Capsaicin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Seratrodast is combined with Captopril.Approved
CarbamazepineThe metabolism of Seratrodast can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Seratrodast is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Seratrodast.Approved
CarprofenThe risk or severity of adverse effects can be increased when Seratrodast is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololSeratrodast may decrease the antihypertensive activities of Carteolol.Approved
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Seratrodast.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Seratrodast is combined with Celecoxib.Approved, Investigational
CeliprololSeratrodast may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Seratrodast can be increased when it is combined with Ceritinib.Approved
CertoparinSeratrodast may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloramphenicolThe metabolism of Seratrodast can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Seratrodast.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Seratrodast.Approved, Vet Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Seratrodast is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Seratrodast.Approved
CholecalciferolThe metabolism of Seratrodast can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Seratrodast resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Seratrodast is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Seratrodast is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Seratrodast is combined with Cilazapril.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Seratrodast.Approved, Investigational
CimicoxibThe risk or severity of adverse effects can be increased when Seratrodast is combined with Cimicoxib.Investigational
CinoxacinSeratrodast may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CisplatinThe risk or severity of adverse effects can be increased when Seratrodast is combined with Cisplatin.Approved
ClarithromycinThe metabolism of Seratrodast can be decreased when combined with Clarithromycin.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Seratrodast is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Seratrodast is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Seratrodast is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Seratrodast is combined with Clonixin.Approved
ClopidogrelThe metabolism of Seratrodast can be decreased when combined with Clopidogrel.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Seratrodast.Vet Approved
CloranololSeratrodast may decrease the antihypertensive activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Seratrodast can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Seratrodast can be decreased when combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Seratrodast resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Seratrodast resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Seratrodast.Approved, Investigational
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Seratrodast is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Seratrodast is combined with Cortisone acetate.Approved, Investigational
CrisaboroleThe metabolism of Seratrodast can be decreased when combined with Crisaborole.Approved, Investigational
CrizotinibThe metabolism of Seratrodast can be decreased when combined with Crizotinib.Approved
CurcuminThe metabolism of Seratrodast can be decreased when combined with Curcumin.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Seratrodast.Experimental
CyclosporineThe metabolism of Seratrodast can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateSeratrodast may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Seratrodast can be decreased when it is combined with Dabrafenib.Approved, Investigational
DalteparinSeratrodast may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidSeratrodast may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanSeratrodast may increase the anticoagulant activities of Darexaban.Investigational
DarunavirThe metabolism of Seratrodast can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Seratrodast can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Seratrodast can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Seratrodast is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Seratrodast is combined with Delapril.Investigational
DelavirdineThe metabolism of Seratrodast can be decreased when combined with Delavirdine.Approved
DesipramineThe metabolism of Seratrodast can be decreased when combined with Desipramine.Approved, Investigational
DesirudinSeratrodast may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Seratrodast is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Seratrodast is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Seratrodast is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Seratrodast is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe serum concentration of Seratrodast can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Seratrodast is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Seratrodast is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Seratrodast.Approved, Investigational
DextranSeratrodast may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibekacinSeratrodast may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Seratrodast is combined with Dibotermin alfa.Approved, Investigational
DicoumarolSeratrodast may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Seratrodast is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Seratrodast is combined with Diflunisal.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Seratrodast is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Seratrodast.Approved
DihydroergotamineThe metabolism of Seratrodast can be decreased when combined with Dihydroergotamine.Approved, Investigational
DihydrostreptomycinSeratrodast may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DiltiazemThe metabolism of Seratrodast can be decreased when combined with Diltiazem.Approved, Investigational
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Seratrodast.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Seratrodast.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Seratrodast.Approved
DosulepinThe metabolism of Seratrodast can be decreased when combined with Dosulepin.Approved
DoxorubicinThe metabolism of Seratrodast can be decreased when combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Seratrodast can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Seratrodast can be decreased when combined with Dronedarone.Approved
DrospirenoneSeratrodast may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Seratrodast is combined with Droxicam.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Seratrodast is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Seratrodast is combined with E-6201.Investigational
Edetic AcidSeratrodast may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanSeratrodast may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe metabolism of Seratrodast can be decreased when combined with Efavirenz.Approved, Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Seratrodast is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Seratrodast is combined with Enalaprilat.Approved
EnoxacinSeratrodast may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinSeratrodast may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Seratrodast.Experimental
EnzalutamideThe serum concentration of Seratrodast can be decreased when it is combined with Enzalutamide.Approved
EpanololSeratrodast may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Seratrodast is combined with Epirizole.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Seratrodast.Experimental
EplerenoneSeratrodast may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Seratrodast.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Seratrodast.Approved
EquileninThe risk or severity of adverse effects can be increased when Seratrodast is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Seratrodast is combined with Equilin.Approved
ErythromycinThe metabolism of Seratrodast can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EsatenololSeratrodast may decrease the antihypertensive activities of Esatenolol.Experimental
Eslicarbazepine acetateThe metabolism of Seratrodast can be decreased when combined with Eslicarbazepine acetate.Approved
EsmololSeratrodast may decrease the antihypertensive activities of Esmolol.Approved
EsomeprazoleThe metabolism of Seratrodast can be decreased when combined with Esomeprazole.Approved, Investigational
EstroneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Seratrodast is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Seratrodast.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Seratrodast is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Seratrodast is combined with Ethenzamide.Experimental
Ethyl biscoumacetateSeratrodast may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Seratrodast is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Seratrodast is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Seratrodast is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Seratrodast is combined with Etoricoxib.Approved, Investigational
EtravirineThe metabolism of Seratrodast can be decreased when combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Seratrodast is combined with Evening primrose oil.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Seratrodast.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Seratrodast is combined with Felbinac.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Seratrodast is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Seratrodast is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Seratrodast.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Seratrodast is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Feprazone.Experimental
Ferulic acidSeratrodast may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Seratrodast.Approved, Investigational
FleroxacinSeratrodast may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Seratrodast.Approved, Withdrawn
FloxuridineThe metabolism of Seratrodast can be decreased when combined with Floxuridine.Approved
FluasteroneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Fluasterone.Investigational
FluconazoleThe metabolism of Seratrodast can be decreased when combined with Fluconazole.Approved, Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Fludrocortisone.Approved, Investigational
FluindioneSeratrodast may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineSeratrodast may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Seratrodast is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Seratrodast is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Seratrodast is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Seratrodast is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Seratrodast is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Fluorometholone.Approved, Investigational
FluorouracilThe metabolism of Seratrodast can be decreased when combined with Fluorouracil.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Seratrodast.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Seratrodast is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Seratrodast is combined with Flurbiprofen.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Seratrodast is combined with Fluticasone furoate.Approved
FluvoxamineThe metabolism of Seratrodast can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Seratrodast.Approved, Nutraceutical, Vet Approved
FondaparinuxSeratrodast may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Seratrodast.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Formestane.Approved, Investigational, Withdrawn
FosamprenavirThe metabolism of Seratrodast can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Seratrodast can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Seratrodast can be increased when combined with Fosphenytoin.Approved, Investigational
FramycetinSeratrodast may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
Fusidic AcidThe serum concentration of Seratrodast can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabexateSeratrodast may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinSeratrodast may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinSeratrodast may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Seratrodast.Approved, Withdrawn
GemfibrozilThe metabolism of Seratrodast can be decreased when combined with Gemfibrozil.Approved
GemifloxacinSeratrodast may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinSeratrodast may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinSeratrodast may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ASeratrodast may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GinsengThe risk or severity of adverse effects can be increased when Seratrodast is combined with Ginseng.Approved, Investigational, Nutraceutical
GrepafloxacinSeratrodast may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Seratrodast is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Seratrodast is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Seratrodast is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Seratrodast is combined with HE3286.Investigational
HeparinSeratrodast may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Seratrodast is combined with Higenamine.Investigational
HydralazineSeratrodast may decrease the antihypertensive activities of Hydralazine.Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Seratrodast.Approved, Investigational
Hygromycin BSeratrodast may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbuproxamThe risk or severity of adverse effects can be increased when Seratrodast is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Seratrodast.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Seratrodast is combined with Icosapent.Approved, Nutraceutical
IdelalisibThe metabolism of Seratrodast can be decreased when combined with Idelalisib.Approved
IdraparinuxSeratrodast may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Seratrodast.Approved, Investigational
ImatinibThe metabolism of Seratrodast can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Seratrodast is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Seratrodast is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Seratrodast.Approved
IndenololSeratrodast may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Seratrodast can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Seratrodast is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Seratrodast is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Seratrodast is combined with Indoprofen.Withdrawn
IrbesartanThe metabolism of Seratrodast can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoleThe serum concentration of Seratrodast can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Seratrodast can be decreased when combined with Isavuconazonium.Approved, Investigational
IsepamicinSeratrodast may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoniazidThe metabolism of Seratrodast can be decreased when combined with Isoniazid.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Seratrodast is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Seratrodast is combined with Istaroxime.Investigational
ItraconazoleThe metabolism of Seratrodast can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Seratrodast can be increased when it is combined with Ivacaftor.Approved
KanamycinSeratrodast may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Kebuzone.Experimental
KetoconazoleThe metabolism of Seratrodast can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Seratrodast is combined with Ketoprofen.Approved, Vet Approved
LandiololSeratrodast may decrease the antihypertensive activities of Landiolol.Investigational
LapatinibThe metabolism of Seratrodast can be decreased when combined with Lapatinib.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Seratrodast.Approved, Investigational
LeflunomideThe metabolism of Seratrodast can be decreased when combined with Leflunomide.Approved, Investigational
LepirudinSeratrodast may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanSeratrodast may increase the anticoagulant activities of Letaxaban.Investigational
LevobetaxololSeratrodast may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololSeratrodast may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinSeratrodast may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Seratrodast.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Seratrodast is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Seratrodast is combined with Lisofylline.Investigational
Lithium cationThe serum concentration of Lithium can be increased when it is combined with Seratrodast.Experimental
LobeglitazoneThe metabolism of Seratrodast can be decreased when combined with Lobeglitazone.Approved, Investigational
LomefloxacinSeratrodast may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Seratrodast is combined with Lonazolac.Experimental
LopinavirThe metabolism of Seratrodast can be decreased when combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Seratrodast is combined with Lornoxicam.Approved, Investigational
LorpiprazoleThe serum concentration of Seratrodast can be increased when it is combined with Lorpiprazole.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Seratrodast is combined with Loteprednol.Approved
LovastatinThe metabolism of Seratrodast can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Seratrodast is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Seratrodast.Approved, Investigational
LuliconazoleThe serum concentration of Seratrodast can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Seratrodast can be increased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Seratrodast is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Seratrodast.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Seratrodast is combined with Magnesium salicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Seratrodast.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Seratrodast is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Seratrodast is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Seratrodast is combined with Mefenamic acid.Approved
MelagatranSeratrodast may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Seratrodast is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Seratrodast is combined with Meloxicam.Approved, Vet Approved
MepindololSeratrodast may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Seratrodast is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Seratrodast.Approved, Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Seratrodast.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Seratrodast.Approved
MetipranololSeratrodast may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Seratrodast.Approved
MibefradilThe metabolism of Seratrodast can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe metabolism of Seratrodast can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MicronomicinSeratrodast may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MidostaurinThe metabolism of Seratrodast can be decreased when combined with Midostaurin.Approved, Investigational
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Seratrodast.Approved, Experimental
MifepristoneThe serum concentration of Seratrodast can be increased when it is combined with Mifepristone.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Seratrodast.Approved
MitotaneThe serum concentration of Seratrodast can be decreased when it is combined with Mitotane.Approved
MizoribineThe risk or severity of adverse effects can be increased when Seratrodast is combined with Mizoribine.Investigational
ModafinilThe metabolism of Seratrodast can be decreased when combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Seratrodast is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Seratrodast.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Seratrodast.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Seratrodast.Approved
NabiloneThe metabolism of Seratrodast can be decreased when combined with Nabilone.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Nabumetone.Approved
NadololSeratrodast may decrease the antihypertensive activities of Nadolol.Approved
NadroparinSeratrodast may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatSeratrodast may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Seratrodast.Approved
Nalidixic AcidSeratrodast may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Seratrodast is combined with NCX 1022.Investigational
NeamineSeratrodast may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololSeratrodast may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Seratrodast can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Seratrodast can be decreased when combined with Nelfinavir.Approved
NemonoxacinSeratrodast may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NepafenacThe risk or severity of adverse effects can be increased when Seratrodast is combined with Nepafenac.Approved, Investigational
NetilmicinSeratrodast may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NetupitantThe serum concentration of Seratrodast can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Seratrodast can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Seratrodast can be decreased when combined with Nicardipine.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Seratrodast is combined with Niflumic Acid.Approved
NilotinibThe metabolism of Seratrodast can be decreased when combined with Nilotinib.Approved, Investigational
NitroaspirinThe risk or severity of adverse effects can be increased when Seratrodast is combined with Nitroaspirin.Investigational
NorfloxacinSeratrodast may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinSeratrodast may increase the neuroexcitatory activities of Ofloxacin.Approved
OlaparibThe metabolism of Seratrodast can be decreased when combined with Olaparib.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Seratrodast.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Seratrodast.Approved
OlsalazineSeratrodast may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Seratrodast is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Seratrodast is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Seratrodast is combined with Orgotein.Vet Approved
OsimertinibThe serum concentration of Seratrodast can be increased when it is combined with Osimertinib.Approved
OtamixabanSeratrodast may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Seratrodast is combined with Oxaprozin.Approved
Oxolinic acidSeratrodast may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololSeratrodast may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Seratrodast.Approved, Withdrawn
PalbociclibThe serum concentration of Seratrodast can be increased when it is combined with Palbociclib.Approved, Investigational
PalmidrolThe risk or severity of adverse effects can be increased when Seratrodast is combined with Palmidrol.Experimental, Nutraceutical
PamidronateThe risk or severity of adverse effects can be increased when Seratrodast is combined with Pamidronate.Approved
PantoprazoleThe metabolism of Seratrodast can be decreased when combined with Pantoprazole.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Seratrodast is combined with Parecoxib.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Seratrodast is combined with Parthenolide.Approved, Investigational
PazufloxacinSeratrodast may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinSeratrodast may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololSeratrodast may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateSeratrodast may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
PentobarbitalThe metabolism of Seratrodast can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
Pentosan PolysulfateSeratrodast may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Seratrodast is combined with Perindopril.Approved
PhenindioneSeratrodast may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe metabolism of Seratrodast can be increased when combined with Phenobarbital.Approved, Investigational
PhenprocoumonSeratrodast may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe metabolism of Seratrodast can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Seratrodast.Approved, Investigational
PindololSeratrodast may decrease the antihypertensive activities of Pindolol.Approved, Investigational
PioglitazoneThe metabolism of Seratrodast can be decreased when combined with Pioglitazone.Approved, Investigational
Pipemidic acidSeratrodast may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Seratrodast.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Seratrodast.Approved, Investigational
Piromidic acidSeratrodast may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Seratrodast is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Seratrodast is combined with Pirprofen.Experimental
PitolisantThe serum concentration of Seratrodast can be decreased when it is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorSeratrodast may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinSeratrodast may decrease the excretion rate of Plazomicin which could result in a higher serum level.Approved, Investigational
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Seratrodast.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Seratrodast is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Seratrodast can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium CitrateSeratrodast may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololSeratrodast may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Seratrodast.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Seratrodast is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Seratrodast is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Seratrodast is combined with Prednicarbate.Approved, Investigational
PrednisoneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Pregnenolone.Approved, Experimental, Investigational
PrimidoneThe metabolism of Seratrodast can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Seratrodast can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Seratrodast is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Seratrodast is combined with Propacetamol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Seratrodast.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Seratrodast.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Seratrodast.Vet Approved
Protein CSeratrodast may increase the anticoagulant activities of Protein C.Approved
Protein S humanSeratrodast may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeSeratrodast may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinSeratrodast may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Seratrodast.Investigational
PuromycinSeratrodast may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrimethamineThe metabolism of Seratrodast can be decreased when combined with Pyrimethamine.Approved, Investigational, Vet Approved
QuazepamThe serum concentration of Seratrodast can be increased when it is combined with Quazepam.Approved, Illicit
QuinaprilThe risk or severity of adverse effects can be increased when Seratrodast is combined with Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Seratrodast.Approved
QuinineThe metabolism of Seratrodast can be decreased when combined with Quinine.Approved
RabeprazoleThe metabolism of Seratrodast can be decreased when combined with Rabeprazole.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Seratrodast is combined with Ramipril.Approved
RanolazineThe metabolism of Seratrodast can be decreased when combined with Ranolazine.Approved, Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Seratrodast is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Seratrodast is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinSeratrodast may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinSeratrodast may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RifabutinThe metabolism of Seratrodast can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe metabolism of Seratrodast can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Seratrodast can be increased when combined with Rifapentine.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Seratrodast.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Seratrodast is combined with Risedronate.Approved, Investigational
RivaroxabanSeratrodast may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Seratrodast is combined with Rofecoxib.Approved, Investigational, Withdrawn
RosoxacinSeratrodast may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RucaparibThe metabolism of Seratrodast can be decreased when combined with Rucaparib.Approved, Investigational
RufloxacinSeratrodast may increase the neuroexcitatory activities of Rufloxacin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Seratrodast.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Seratrodast is combined with Salicylamide.Approved
SalsalateThe risk or severity of adverse effects can be increased when Seratrodast is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Seratrodast.Experimental
SaquinavirThe metabolism of Seratrodast can be decreased when combined with Saquinavir.Approved, Investigational
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Seratrodast.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Seratrodast.Approved, Investigational
SecobarbitalThe metabolism of Seratrodast can be increased when combined with Secobarbital.Approved, Vet Approved
SeliciclibThe risk or severity of adverse effects can be increased when Seratrodast is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Seratrodast is combined with Semapimod.Investigational
SerrapeptaseThe risk or severity of adverse effects can be increased when Seratrodast is combined with Serrapeptase.Investigational
SertralineThe metabolism of Seratrodast can be decreased when combined with Sertraline.Approved
SildenafilThe metabolism of Seratrodast can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Seratrodast can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Seratrodast can be increased when it is combined with Simeprevir.Approved
SisomicinSeratrodast may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinSeratrodast may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
SorafenibThe metabolism of Seratrodast can be decreased when combined with Sorafenib.Approved, Investigational
SotalolSeratrodast may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinSeratrodast may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Seratrodast is combined with Spirapril.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Seratrodast.Investigational
St. John's WortThe serum concentration of Seratrodast can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Seratrodast can be increased when it is combined with Stiripentol.Approved
StreptomycinSeratrodast may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
SulfadiazineThe metabolism of Seratrodast can be decreased when combined with Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleThe metabolism of Seratrodast can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Seratrodast can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulodexideSeratrodast may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Seratrodast.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Seratrodast is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Suxibuzone.Experimental
TacrolimusSeratrodast may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Seratrodast.Approved
TalinololSeratrodast may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Seratrodast.Approved
TamoxifenThe metabolism of Seratrodast can be decreased when combined with Tamoxifen.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Seratrodast.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Seratrodast.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Seratrodast is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Seratrodast is combined with Technetium Tc-99m medronate.Approved
TelaprevirThe metabolism of Seratrodast can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Seratrodast can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Seratrodast.Approved, Investigational
TemafloxacinSeratrodast may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Seratrodast is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Seratrodast is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Seratrodast is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Seratrodast is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Seratrodast is combined with Tepoxalin.Vet Approved
TerbutalineSeratrodast may decrease the antihypertensive activities of Terbutaline.Approved
TeriflunomideThe metabolism of Seratrodast can be decreased when combined with Teriflunomide.Approved
TertatololSeratrodast may decrease the antihypertensive activities of Tertatolol.Experimental
ThiotepaThe metabolism of Seratrodast can be decreased when combined with Thiotepa.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Seratrodast is combined with Tiaprofenic acid.Approved
TicagrelorThe metabolism of Seratrodast can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Seratrodast can be decreased when combined with Ticlopidine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Seratrodast is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololSeratrodast may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Seratrodast is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Seratrodast is combined with Tixocortol.Approved, Withdrawn
TobramycinSeratrodast may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TocilizumabThe serum concentration of Seratrodast can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Seratrodast can be decreased when combined with Tolbutamide.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Seratrodast is combined with Tolmetin.Approved
TopiroxostatThe metabolism of Seratrodast can be decreased when combined with Topiroxostat.Approved, Investigational
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Seratrodast.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Seratrodast is combined with Trandolapril.Approved
TranylcypromineThe metabolism of Seratrodast can be decreased when combined with Tranylcypromine.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Seratrodast.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Seratrodast.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Triamcinolone.Approved, Vet Approved
TriamtereneSeratrodast may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Seratrodast is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Seratrodast.Approved, Vet Approved
TrimethoprimThe metabolism of Seratrodast can be decreased when combined with Trimethoprim.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Seratrodast is combined with Triptolide.Investigational
TrovafloxacinSeratrodast may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinSeratrodast may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Seratrodast is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Seratrodast.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Seratrodast is combined with Valdecoxib.Approved, Investigational, Withdrawn
ValsartanThe metabolism of Seratrodast can be decreased when combined with Valsartan.Approved, Investigational
VemurafenibThe serum concentration of Seratrodast can be decreased when it is combined with Vemurafenib.Approved
VerapamilThe metabolism of Seratrodast can be decreased when combined with Verapamil.Approved
VoriconazoleThe metabolism of Seratrodast can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinSeratrodast may increase the anticoagulant activities of Warfarin.Approved
XimelagatranSeratrodast may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZafirlukastThe metabolism of Seratrodast can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Seratrodast.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Seratrodast.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Seratrodast can be decreased when combined with Ziprasidone.Approved
ZofenoprilThe risk or severity of adverse effects can be increased when Seratrodast is combined with Zofenopril.Experimental
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Seratrodast.Withdrawn
ZucapsaicinThe metabolism of Seratrodast can be decreased when combined with Zucapsaicin.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Drug
D01123
PubChem Compound
2449
PubChem Substance
347827787
ChemSpider
2355
BindingDB
50018528
ChEBI
32126
ChEMBL
CHEMBL70972
Wikipedia
Seratrodast
ATC Codes
R03DX06 — Seratrodast

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00359 mg/mLALOGPS
logP3.35ALOGPS
logP5.37ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)4.3ChemAxon
pKa (Strongest Basic)-7.9ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area71.44 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity102.37 m3·mol-1ChemAxon
Polarizability39.77 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dalbergiones. These are quinone derivatives containing a dalbergione moiety, which consists of a 1-4 quinone conjugated to a phenyl group at ring carbon 2.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Neoflavonoids
Sub Class
Dalbergiones
Direct Parent
Dalbergiones
Alternative Parents
Monocyclic monoterpenoids / Aromatic monoterpenoids / P-benzoquinones / Medium-chain fatty acids / Benzene and substituted derivatives / Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives
Substituents
Dalbergione skeleton / Aromatic monoterpenoid / Monocyclic monoterpenoid / Monoterpenoid / Medium-chain fatty acid / Quinone / P-benzoquinone / Monocyclic benzene moiety / Fatty acyl / Benzenoid
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Thromboxane a2 receptor activity
Specific Function
Receptor for thromboxane A2 (TXA2), a potent stimulator of platelet aggregation. The activity of this receptor is mediated by a G-protein that activates a phosphatidylinositol-calcium second messen...
Gene Name
TBXA2R
Uniprot ID
P21731
Uniprot Name
Thromboxane A2 receptor
Molecular Weight
37430.69 Da
References
  1. Endo S, Akiyama K: [Thromboxane A2 receptor antagonist in asthma therapy]. Nihon Rinsho. 1996 Nov;54(11):3045-8. [PubMed:8950952]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks trans...
Gene Name
UGT1A9
Uniprot ID
O60656
Uniprot Name
UDP-glucuronosyltransferase 1-9
Molecular Weight
59940.495 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
Gene Name
CYP2A6
Uniprot ID
P11509
Uniprot Name
Cytochrome P450 2A6
Molecular Weight
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on August 31, 2010 15:13 / Updated on August 02, 2018 05:39